key: cord-0688430-1ggrjy9b authors: Yang, Luhuan; Liu, Jinglan; Zhang, Rong; Li, Mingwu; Li, Zifeng; Zhou, Xiaojing; Hu, Chuanjun; Tian, Fei; Zhou, Fating; Lei, Yunhong title: Epidemiological and clinical features of 200 hospitalized patients with Corona Virus Disease 2019 outside Wuhan, China: A descriptive study date: 2020-05-26 journal: J Clin Virol DOI: 10.1016/j.jcv.2020.104475 sha: d6582d45b6a300a710b2bb94ea6fb52cdbd265d8 doc_id: 688430 cord_uid: 1ggrjy9b BACKGROUND: The recent outbreak of coronavirus disease 2019 (COVID-19) has spread worldwide, with especially severe epidemics occurring in cities across China. OBJECTIVES: To report the epidemiological and clinical futures of the 200 patients infected with COVID-19 in Yichang, Hubei Province, China. STUDY DESIGN: 200 patients confirmed with COVID-19 in a designated hospital in Yichang from Jan 30 to Feb 8, 2020 were investigated retrospectively. The epidemiological data and clinical characteristics were collected. The data between the ICU patients and non-ICU patients were compared. The patients were followed up till Feb 26, 2020. RESULTS: Of the 200 hospitalized patients with COVID-19, 98 (49.0%) were male, and the mean age was 55 years. Eighty-seven (43.5%) had no linkage to Wuhan or contact history. Familial clustering was found in 34 patients. Sixtyfive (32.5%) suffered from chronic diseases. The common symptoms included fever (171[85.5%]), cough (116[58.0%]), and fatigue (64[32%]). Most patients had lymphopenia. One hundred and seventy-two (86%) patients showed typical imaging findings of viral pneumonia. Most patients received antiviral, antibiotic, and corticosteroid treatment. Compared with the non-ICU patients, 29 (14.5%) patients in the ICU were older and more likely to show dyspnea and complications including ARDS. As of Feb 26, 15 (51.7%) patients in the ICU had died. CONCLUSIONS: The COVID-19 infection was of clustering onset and can cause severe respiratory disease and even death. The mortality of ICU patients with COVID-19 was considerably high. In December 2019, a new pneumonia case of unknown etiology emerged and began to widely spread in Wuhan, Hubei Province, China. Most of the patients were epidemiologically linked to the Huanan Seafood Wholesale Market, indicating animalto-human disease transmission mode, but soon there was considerable evidence to confirm the human-to-human transmission 1, 2 . Within two weeks after the outbreak, the Chinese Center for Disease Control (CDC) isolated samples from the lower respiratory tracts of patients for deep sequencing analysis, suggesting the emergence of a novel coronavirus, which was officially named SARS-CoV-2 by WHO on Feb 11, 2020. Since the SARS-CoV-2 has characteristics typical of the coronavirus family, it is currently classified in the lineage B betacoronaviruses that also include severe acute respiratory syndrome (SARS) and middle eastern respiratory syndrome (MERS) [3] [4] [5] [6] . Although the source of the SARS-CoV-2 is still under investigation, genome sequencing and phylogenetic analysis proved that the sequence of RNA genome of the virus is similar to bat coronaviruses, indicating the bats maybe the primary source 7 . The disease caused by the SARS-CoV-2 was officially named Corona Virus Disease 2019 (COVID-19) by WHO 8 . Previous studies showed that the clinical manifestations of patients with COVID-19 in Wuhan mainly included fever, chill, cough, difficulty in breathing, muscle soreness, fatigue, and complications such as acute respiratory distress syndrome (ARDS), acute kidney injury, acute cardiac injury, etc 9 . Laboratory tests showed that the leukocytes were normal or decreased, and/or the J o u r n a l P r e -p r o o f lymphocytes decreased. Chest imaging revealed typical features of viral pneumonia 10 . Wang et al reported that among the 138 investigated patients, 36 received ICU care, with a mortality of 4.3%. It was found that COVID-19 was of clustering onset, and that older men with comorbidities were more likely to develop into critically ill patients 11 . Although the government adopted a series of measures to respond to this major public health emergency, such as prohibiting citizens from leaving or coming into Wuhan and group activities, in the following dozens of days, a large cluster of the [14] [15] [16] . However, the information on the epidemiological and clinical features of COVID-19 in other areas is scarce. The main purpose of this study was to comprehensively analyze and compare the epidemiological, clinical, laboratory, radiological, treatment, and outcome data of confirmed patients with COVID-19 admitted in a designated hospital in Yichang, Hubei Province, China. We hope our findings can provide some references for understanding J o u r n a l P r e -p r o o f 6 the epidemic and the clinical characteristics of this novel coronavirus outside Wuhan. The epidemiological, clinical, laboratory, treatment, and outcome data of the patients were obtained from electronic medical records. All the data were reviewed by two We described and summarized demographic data, family clustering, exposure history, potential comorbidities, clinical manifestations, laboratory tests, chest CT scans, treatment measures, and prognosis. All statistical analyses were performed using SPSS20.0 version software. Continuous variables were represented as mean, median, and interquartile range (IQR) values. Independent group t-test was used to compare the means of continuous variables when the data were normally distributed. Categorical variables were represented as frequency and percentage. The Mann-Whitney test was used when the data were non-normally distributed. Chi-square test was used to compare proportions of categorical variables, although Fisher's exact test was used in cases where data was limited. A two-sided α of less than 0·05 was considered statistically significant. A total of 200 patients with laboratory-confirmed COVID-19 were enrolled in the study. (Table 1) . According to chest CT on admission, 176 (86%) patients had bilateral involvement (Table 2 ). Many of the patients presented with complications, including 32 (16%) with acute respiratory distress syndrome (ARDS), 10(%) with acute cardiac injury, 24 (12%) with acute renal injury, 12 (6.0%) with secondary infection, and 4 (2%) with shock (Table 3 ). And it was found that the complications were more common in the ICU patients Herein, we reported a total of 200 patients with confirmed COVID- 19 Visualization, Investigation. Mingwu Li: Project administration, Methodology. Fei Tian: Formal analysis. Fating Zhou: Investigation. Xiaojing Zhou: Investigation, Supervision. Chuanjun Hu: Software, Validation. Zifeng Li: Methodology Coronavirus Disease 2019: Implications of Emerging Infections for Transplantation Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak A case of hypermucoviscous Klebsiella pneumoniae liver abscess syndrome in an Iraqi male Artery tortuosity syndrome exhibiting early-onset emphysema with novel compound heterozygous SLC2A10 mutations Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Surveillance for emerging respiratory viruses A pneumonia outbreak associated with a new coronavirus of probable bat origin Wuhan novel coronavirus (COVID-19): why global control is challenging? First Case of 2019 Novel Coronavirus in the United States Characteristics of fever and response to antipyretic therapy in military personnel with adenovirus-positive community-acquired pneumonia Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Update: Public Health Response to the Coronavirus Disease Gross and Histopathological Findings in the First Reported Vaping-Induced Lung Injury Death in the United States 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation Covid-19: preparedness, decentralisation, and the hunt for patient zero Preventing a covid-19 pandemic Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study World Health Organization declares Global Emergency: A review of the 2019 Novel Coronavirus (COVID-19) Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV Pathological findings of COVID-19 associated with acute respiratory distress syndrome Clinical and computed tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2 Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study Clinical Characteristics of Coronavirus Disease 2019 in China Potential Interventions for Novel Coronavirus in China: A Systematic Review Management strategies of neonatal jaundice during the coronavirus disease 2019 outbreak Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients The SARS, MERS and novel coronavirus epidemics, the newest and biggest global health threats: what lessons have we learned? We thank all participating patients and their families, as well as staffs of all the institutions involved in this study. None declared.